Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial

Russell L Rothman,Thomas G Stewart,Ahmad Mourad,David Boulware,Matthew W McCarthy,Florence Thicklin,Idania T Garcia del Sol,Jose Luis Garcia,Carolyn Bramante,Nirav S Shah,Upinder Singh,John C Williamson,Paulina A Rebolledo,Prasanna C Jagannathan,Tiffany Schwasinger-Schmidt,Adit A Ginde,Mario Castro,Dushyantha Jayaweera,Mark Sulkowski,Nina Gentile,Kathleen McTigue,G. Michael Felker,Allison DeLong,Rhonda Wilder,Sean Collins,Sarah E Dunsmore,Stacey J Adam,George J Hanna,Elizabeth Shenkman,Adrian F. Hernandez,Susanna Naggie,Christopher J Lindsell

DOI: https://doi.org/10.1101/2024.05.16.24307115

2024-05-18

Abstract:Importance: The effect of montelukast in reducing symptom duration among outpatients with mild to moderate coronavirus disease 2019 (COVID-19) is uncertain. Objective: To assess the effectiveness of montelukast compared with placebo, in treating outpatients with mild to moderate COVID-19. Design, Setting, and Participants: The ACTIV-6 platform randomized clinical trial aims to evaluate the effectiveness of repurposed medications in treating mild to moderate COVID-19. Between January 27, 2023, and June 23, 2023, 1250 participants >=30 years of age with confirmed SARS-CoV-2 infection and >=2 acute COVID-19 symptoms for <=7 days, were included across 104 US sites to evaluate the use of montelukast. Interventions: Participants were randomized to receive montelukast 10 mg once daily or matched placebo for 14 days. Main Outcomes and Measures: The primary outcome was time to sustained recovery (defined as at least 3 consecutive days without symptoms). Secondary outcomes included time to death; time to hospitalization or death; a composite of hospitalization, urgent care visit, emergency department visit, or death; COVID clinical progression scale; and difference in mean time unwell. Results: Among participants who were randomized and received study drug, the median age was 53 years (IQR 42-62), 60.2% were female, 64.6% identified as Hispanic/Latino, and 56.3% reported >=2 doses of a SARS-CoV-2 vaccine. Among 628 participants who received montelukast and 622 who received placebo, differences in time to sustained recovery were not observed (adjusted hazard ratio [HR] 1.02; 95% credible interval [CrI] 0.92-1.12; P(efficacy) = 0.63]). Unadjusted median time to sustained recovery was 10 days (95% confidence interval 10-11) in both groups. No deaths were reported and 2 hospitalizations were reported in each group; 36 participants reported healthcare utilization events (a priori defined as death, hospitalization, emergency department/urgent care visit); 18 in the montelukast group compared with 18 in the placebo group (HR 1.01; 95% CrI 0.45-1.84; P(efficacy)=0.48). Five participants experienced serious adverse events (3 with montelukast and 2 with placebo). Conclusions and Relevance: Among outpatients with mild to moderate COVID-19, treatment with montelukast does not reduce duration of COVID-19 symptoms.

What problem does this paper attempt to address?

This paper is a randomized clinical trial called ACTIV-6, aiming to investigate the impact of Montelukast compared to placebo on the recovery time of mild to moderate COVID-19 outpatient patients. The study found that Montelukast did not significantly reduce the duration of COVID-19 symptoms, and no significant differences were observed compared to the placebo group. The primary outcome was the time of being symptom-free for at least three consecutive days, with a median of 10 days in both groups. Furthermore, there were no significant differences between the two groups in terms of death, hospitalization, or emergency medical events. Therefore, the conclusion of the paper points out that Montelukast treatment does not shorten the duration of disease symptoms in mild to moderate COVID-19 outpatient patients.